OATD-01

OATD-01 is an orally administered, once-daily, first-in-class and highly selective small molecule inhibitor of chitinase-1 (CHIT1), also known as chitotriosidase. It is being developed primarily for the treatment of pulmonary sarcoidosis—a granulomatous inflammatory disease affecting the lungs—by targeting CHIT1 to reduce inflammation and fibrosis. The drug has demonstrated potent anti-inflammatory and antifibrotic effects in preclinical models and has shown high therapeutic potential in other inflammatory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH). OATD-01 is currently in Phase 2 clinical trials for pulmonary sarcoidosis. Molecure is the main developer of this drug, which originated from Yale University research. The compound has received orphan drug designation for sarcoidosis and IPF[1][2][3][5][6].

Other names

5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine